PT Saptausaha Gemilangindah Tbk (IDX:SAGE)
35.00
+2.00 (6.06%)
At close: Feb 27, 2026
IDX:SAGE Revenue
PT Saptausaha Gemilangindah Tbk had revenue of 1.05B IDR in the quarter ending September 30, 2025, a decrease of -78.66%. This brings the company's revenue in the last twelve months to 5.54B, down -66.56% year-over-year. In the year 2024, PT Saptausaha Gemilangindah Tbk had annual revenue of 16.89B, down -23.08%.
Revenue (ttm)
5.54B
Revenue Growth
-66.56%
P/S Ratio
50.72
Revenue / Employee
97.25M
Employees
57
Market Cap
281.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16.89B | -5.07B | -23.08% |
| Dec 31, 2023 | 21.96B | -13.65B | -38.32% |
| Dec 31, 2022 | 35.61B | 9.60B | 36.91% |
| Dec 31, 2021 | 26.01B | 22.53B | 647.83% |
| Dec 31, 2020 | 3.48B | 3.15B | 949.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PT Perdana Gapuraprima Tbk | 480.80B |
| PT Citra Buana Prasida Tbk | 90.52B |
| PT Cahayasakti Investindo Sukses Tbk | 86.94B |
| PT Winner Nusantara Jaya Tbk | 62.53B |
| PT Graha Mitra Asia Tbk | 49.31B |
| PT Grand House Mulia Tbk | 38.69B |
| PT Minahasa Membangun Hebat Tbk | 33.98B |
| PT Puri Global Sukses Tbk | 28.87B |
PT Saptausaha Gemilangindah Tbk News
- 7 months ago - Sage Therapeutics Announces Second Quarter 2025 Financial Results - Business Wire
- 8 months ago - SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE - Business Wire
- 8 months ago - Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary - GlobeNewsWire
- 9 months ago - These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Benzinga
- 9 months ago - Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect - Accesswire
- 9 months ago - Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 9 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. - PRNewsWire
- 9 months ago - Sage Therapeutics Stock Soars 35% After Sale to Supernus. What We Know. - Barrons